Patent · US Active

E2F as a target of hormone refractory prostate cancer

US8822421B2 · kind B2 · utility

2Cited by

0References

11Claims

0Family size

Assignee

Rutgers, the State University of New Jersey · US

Inventors

Joseph R. Bertino · Branford, US
Debabrata Banerjee · Floral Park, US
Tamara Minko · Edison, US
Olga B. Garbuzenko · Highland Park, US
Xiaoqi Xie · Lawrenceville, US
John E. Kerrigan · Plainsboro, US
Emine E. Abali · Tenafly, US
Kathleen W. Scotto · Middle Village, US

Key dates

Filing date	Oct 14, 2011
Grant date	Sep 2, 2014
Priority date	—
Expiry date	Oct 14, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/4703
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.